therapeut
target
host
cell
factor
requir
viru
replic
rather
pathogen
compon
open
new
perspect
counteract
viru
infect
anticip
advantag
approach
includ
heighten
barrier
develop
viral
resist
broaden
pathogen
target
spectrum
myxovirus
predominantli
associ
acut
diseas
thu
particularli
attract
approach
sinc
treatment
time
kept
limit
identifi
inhibitor
candid
analyz
hit
compound
emerg
largescal
highthroughput
screen
abil
block
replic
member
orthomyxoviru
paramyxoviru
famili
return
compound
class
broad
antivir
activ
includ
potent
inhibit
differ
influenza
viru
paramyxoviru
strain
hittolead
chemistri
inhibitori
concentr
nanomolar
rang
context
immort
cell
line
human
pbmc
compound
show
high
metabol
stabil
expos
human
hepatocyt
subcellular
fraction
antivir
activ
hostcel
speci
specif
pronounc
cell
higher
mammalian
origin
support
hostcel
target
compound
induc
temporari
cell
cycl
arrest
host
mrna
protein
biosynthesi
larg
unaffect
treat
cell
maintain
full
metabol
activ
viral
replic
block
postentri
step
resembl
inhibit
profil
known
inhibitor
viral
rnadepend
rnapolymeras
rdrp
activ
direct
assess
rdrp
activ
presenc
reagent
reveal
strong
inhibit
context
viral
infect
reporterbas
minireplicon
assay
toto
identifi
compound
class
broad
viral
target
rang
block
host
factor
requir
viral
rdrp
activ
viral
adapt
attempt
induc
resist
prolong
exposur
contrast
rapid
adapt
pathogendirect
inhibitor
rdrp
activ
myxovirus
envelop
negativestrand
rna
virus
transmit
respiratori
rout
orthomyxoviru
famili
compris
five
differ
genera
influenza
virus
clinic
relev
paramyxovirida
respiratori
syncyti
viru
rsv
measl
viru
mev
mump
viru
muv
human
parainfluenzavirus
hpiv
recent
emerg
highli
pathogen
zoonot
henipavirus
constitut
major
human
pathogen
although
clinic
complic
associ
myxovirus
involv
persist
infect
virus
predominantli
induc
acut
respiratori
system
diseas
collect
myxovirus
respons
major
human
morbid
mortal
due
viral
respiratori
ill
global
particular
influenza
viru
lead
caus
morbid
mortal
respiratori
diseas
north
america
despit
exist
vaccin
prophylaxi
due
fact
vaccin
current
use
reduc
ill
approxim
healthi
adult
homolog
preval
circul
viru
protect
elderli
reach
approxim
vaccin
efficaci
reduc
substanti
circul
strain
differ
constitut
vaccin
despit
extens
research
contrast
instanc
mev
muv
vaccin
current
avail
sever
major
pathogen
paramyxoviru
famili
rsv
differ
hpiv
infect
rsv
lead
caus
pneumonia
bronchiol
infant
associ
signific
mortal
hpiv
type
primari
caus
croup
syndrom
likewis
result
seriou
lower
respiratori
diseas
pneumonia
bronchiol
avail
effect
antivir
therapi
clinic
signific
myxoviru
infect
limit
licens
neuraminidas
inhibitor
influenza
therapi
zanamivir
oseltamivir
show
efficaci
administ
within
window
onset
symptom
increasingli
compromis
preexist
emerg
viral
resist
ribavirin
although
approv
rsv
treatment
show
limit
util
due
efficaci
toxic
issu
polyclon
immunoglobulin
rsvivig
human
monoclon
antibodi
synagi
provid
rsv
prophylaxi
use
limit
highrisk
pediatr
patient
consid
high
mutat
rate
seen
particular
rna
virus
develop
novel
type
myxoviru
inhibitor
circumv
rapid
develop
resist
highli
desir
strategi
conceiv
toward
goal
target
host
factor
requir
complet
viral
life
cycl
rather
pathogenencod
factor
directli
receiv
heighten
interest
recent
year
approach
expect
establish
signific
barrier
spontan
viral
escap
inhibit
sinc
individu
viral
mutat
less
like
compens
loss
essenti
host
cofactor
prevent
highaffin
bind
convent
pathogendirect
antivir
given
degre
overlap
host
cell
pathway
requir
success
replic
relat
viral
pathogen
hostdirect
antivir
approach
also
potenti
move
beyond
onebug
onedrug
paradigm
broaden
pathogen
target
rang
chemic
scaffold
natur
target
host
factor
antivir
therapi
bear
inher
higher
potenti
undesir
druginduc
side
effect
convent
pathogendirect
strategi
approach
nevertheless
investig
treatment
chronic
viral
infect
applic
inhibit
infect
pathogen
predominantli
associ
sever
acut
diseas
member
myxoviru
famili
anticip
render
drugrel
side
effect
toler
extent
sinc
necessari
treatment
time
concomit
host
exposur
drug
remain
limit
case
influenza
infect
instanc
typic
neuraminidas
inhibitor
regimen
consist
twice
daili
administr
fiveday
period
treatment
period
prophylaxi
reli
broaden
antimyxoviru
target
spectrum
main
select
criterion
secondari
screen
assay
mine
result
recent
complet
high
throughput
chemic
librari
screen
identifi
hit
candid
possibl
hostdirect
mechan
action
yield
compound
class
broad
antivir
activ
subject
synthet
scaffold
optim
quantif
activ
concentr
select
group
clinic
relev
orthoand
paramyxoviru
famili
member
test
panel
expos
host
cell
differ
speci
origin
character
compoundinduc
pointofarrest
viral
life
cycl
progress
viral
adapt
growth
presenc
inhibitor
employ
compar
escap
rate
inhibit
new
compound
class
wellcharacter
pathogendirect
antivir
identifi
smallmolecul
hit
candid
block
myxoviru
life
cycl
hostdirect
mechan
analyz
result
highthroughput
cellbas
antimev
screen
librari
nih
divers
set
recent
report
primari
screen
agent
serv
myxoviru
repres
wild
type
mev
isol
mvi
mevalaska
chosen
base
eas
growth
readili
quantifi
cytopath
effect
autom
system
search
candid
hostdirect
antivir
profil
anticip
three
distinct
featur
desir
compound
potent
inhibit
viru
replic
screen
concentr
mm
b
primari
screen
score
repres
select
index
cc
ec
close
cutoff
valu
hit
candid
due
anticip
hostcel
interfer
c
broaden
viral
target
spectrum
counterscreen
assay
extend
pathogen
myxoviru
famili
inhibit
paramyxoviru
famili
member
assess
six
compound
effici
block
close
relat
canin
distemp
viru
cdv
distantli
relat
human
parainfluenzaviru
type
addit
mevalaska
leav
cell
metabol
activ
essenti
unaffect
independ
hit
three
share
common
molecular
scaffold
figur
sinc
ht
score
analog
best
match
target
criteria
antivir
activ
highest
group
subject
character
development
effort
synthet
optim
structur
confirm
scaffold
return
lead
analog
figur
show
potent
activ
mev
select
clinic
signific
member
paraand
orthomyxoviru
famili
albeit
lesser
degre
repres
posit
strand
rna
viru
sindbi
viru
alphavirida
dna
viru
vaccinia
viru
poxvirida
famili
figur
inhibitori
concentr
larger
panel
myxoviru
famili
member
summar
tabl
observ
primari
hit
compound
metabol
activ
differ
establish
cell
line
expos
unchang
mm
highest
assess
concentr
base
solubl
substanc
growth
media
figur
tabl
differ
primari
human
cell
examin
metabol
activ
unaffect
pbmc
smooth
muscl
cell
slightli
affect
bronchial
epitheli
cell
compound
figur
data
support
potent
antimyxoviru
activ
compound
activ
concentr
rang
nm
depend
target
viru
explor
whether
meet
profil
hostdirect
antivir
examin
whether
extent
inhibit
determin
speci
origin
host
cell
use
viru
propag
base
broad
host
cell
rang
inhibit
influenza
awsn
replic
monitor
addit
higher
mammalian
atcc
hela
atcc
mdck
atcc
cell
line
cell
rodent
atcc
mel
atcc
atcc
cho
atcc
avian
atcc
origin
test
permiss
influenza
awsn
infect
tabl
inhibitori
concentr
obtain
higher
mammalian
cell
line
examin
similar
awsn
inhibit
found
inact
rodent
cell
line
viru
propag
murin
avian
cell
tabl
howev
inhibitori
activ
extend
fulli
primari
human
pbmc
figur
latter
inhibit
mevalaska
monitor
due
effici
growth
mev
isol
pbmc
host
cell
speci
effect
antivir
activ
consist
specif
target
cellular
factor
compound
argu
dock
conserv
viral
factor
undesir
promiscu
unspecif
mode
activ
central
found
chemic
scaffold
may
render
compound
suscept
rapid
phase
oxid
vivo
thu
possibl
compromis
development
potenti
test
metabol
stabil
substanc
earli
develop
expos
human
hepatocyt
subcellular
fraction
vitro
indic
phase
metabol
exposur
approxim
input
materi
remain
intact
correspond
extrapol
halflif
approxim
minut
figur
unstabl
analog
figur
return
half
live
minut
assay
respect
confirm
metabol
compet
fraction
use
assess
stabil
human
plasma
comparison
unstabl
procain
stabl
procainamid
tabl
activ
ec
toxic
cc
determin
veroslam
cell
concentr
select
clinic
relev
paraand
orthomyxoviru
famili
member
comparison
activ
concentr
previous
character
mevspecif
inhibitor
viral
rdrp
complex
corrobor
result
sinc
integr
virtual
unaffect
incub
period
figur
taken
togeth
find
suggest
desir
metabol
stabil
scaffold
recommend
mechanist
character
data
corrobor
good
metabol
stabil
report
structur
similar
compound
figur
nonnucleosid
inhibitor
hiv
revers
transcriptas
clinic
preced
share
lack
mev
inhibitori
activ
assay
data
shown
sinc
direct
cytotox
low
cell
line
examin
next
test
effect
substanc
cell
cycl
progress
analysi
dna
content
cell
continu
treat
hour
flow
cytometri
reveal
accumul
cell
singl
popul
dna
content
close
resembl
profil
refer
cell
popul
expos
hydroxyurea
markedli
differ
dna
content
nocodazoletr
cell
figur
nocodazol
interfer
microtubul
polymer
result
g
arrest
wherea
hydroxyurea
thought
lead
arrest
g
sphase
deplet
cellular
dntp
pool
explor
effect
cell
cycl
progress
monitor
phosphoryl
statu
b
kinas
exposur
cell
either
compound
hydroxyurea
nocodazol
alsterpaullon
nanomolar
small
molecul
inhibitor
cyclindepend
kinas
reportedli
induc
potent
g
sphase
cell
cycl
arrest
pivot
regul
g
transit
b
kinas
inactiv
phosphoryl
g
phase
accumul
phosphoryl
form
thu
indic
g
arrest
hydroxyureaand
alsterpaullonetr
control
exposur
cell
result
increas
steadi
state
level
phosphoryl
b
kinas
support
g
phase
arrest
figur
test
whether
arrest
perman
temporari
next
incub
cell
presenc
compound
vehicl
alon
hour
follow
remov
substanc
reseed
cell
ident
densiti
monitor
cell
growth
addit
incub
period
absenc
reveal
prolifer
rate
resum
untreat
control
cell
remov
compound
figur
indic
revers
growth
arrest
contrast
member
orthomyxoviru
famili
paramyxoviru
replic
take
place
cytosol
thu
consid
immedi
depend
activ
cell
prolifer
fact
mev
shown
induc
g
arrest
infect
lymphoyct
confirm
cell
cycl
progress
requir
viru
replic
directli
test
whether
growth
arrest
per
se
causal
antivir
effect
compound
gener
mevalaska
inhibit
curv
comparison
cyclindepend
kinas
inhibitor
alsterpaullon
even
highest
concentr
assess
mm
alsterpaullon
caus
margin
reduct
mev
yield
figur
find
indic
antivir
effect
base
upstream
effect
compound
rather
consequ
cell
cycl
arrest
cellular
mrna
product
protein
biosynthesi
unperturb
explor
whether
growth
arrest
treat
cell
coincid
reduc
host
cell
rna
synthesi
overal
cell
protein
biosynthesi
next
assess
effect
host
mrna
protein
product
rel
level
three
signatur
host
mrna
short
half
live
determin
real
time
pcr
incub
cell
presenc
differ
concentr
rang
mm
case
mrna
level
cell
similar
vehicletr
refer
exposur
actinomycin
block
rna
synthesi
arrest
transcript
initi
complex
result
major
reduct
rel
mrna
level
figur
immunodetect
cellular
gapdh
plasmidencod
mev
f
protein
control
cmv
promot
demonstr
product
transcript
presenc
compound
furthermor
coincid
uninterrupt
translat
case
f
cotransl
insert
host
secretori
system
figur
furthermor
equival
level
proteolyt
process
f
materi
vehicleexpos
cell
indic
intracellular
vesicular
transport
remain
intact
presenc
sinc
cleavag
mediat
cellular
proteas
furin
lategolgi
compart
contrast
hostencod
transient
express
protein
express
virusencod
protein
context
paramyxoviru
orthomyxoviru
infect
fulli
block
nm
figur
thu
observ
demonstr
compound
effici
suppress
express
virusencod
protein
due
gener
interfer
inhibitor
cellular
mrna
synthesi
translat
phenotyp
suggest
possibl
interfer
earli
step
viral
life
cycl
entri
viral
rdrp
activ
basi
antivir
activ
differenti
altern
identifi
point
arrest
viral
life
cycl
induc
first
examin
whether
compound
block
membran
fusion
thu
viral
entri
express
plasmidencod
paramyxoviru
envelop
glycoprotein
receptorposit
cell
typic
result
extens
celltocel
fusion
hallmark
cytopath
effect
associ
paramyxoviru
infect
vitro
transient
membran
fusion
assay
allow
quantit
assess
whether
inhibitor
block
viral
entri
postentri
step
viral
life
cycl
examin
mev
glycoproteinmedi
celltocel
fusion
microscop
figur
luciferas
reporterbas
quantit
celltocel
fusion
assay
figur
presenc
observ
extens
membran
fusion
indistinguish
seen
vehicletr
control
indic
compound
act
entri
inhibitor
determin
whether
predispos
host
cell
viral
infect
induc
antivir
state
pretreat
cell
compound
follow
washout
substanc
viru
infect
differ
time
period
independ
incub
time
remov
compound
could
detect
substanti
inhibitori
effect
setup
figur
argu
prime
innat
antivir
respons
likewis
preincub
viral
particl
prior
remov
articl
infect
lack
appreci
antivir
effect
figur
exclud
direct
virucid
activ
substanc
ad
timeofaddit
experi
distinct
time
point
postinfect
comparison
two
previous
character
pathogentarget
antivir
inhibit
profil
distinct
entri
inhibitor
close
resembl
profil
rdrp
blocker
class
figur
thu
data
point
toward
inhibit
viral
rdrp
activ
one
possibl
underli
mechan
antivir
activ
compound
myxoviru
infect
viral
rdrp
complex
mediat
genom
transcript
replic
express
viral
protein
gener
progeni
genom
respect
replic
occur
gener
antigenom
posit
polar
serv
templat
neg
strand
genom
synthesi
directli
test
whether
affect
viral
rdrp
activ
context
viru
infect
determin
copi
number
mevalaska
mrna
antigenom
infect
compoundtr
cell
rel
vehicletr
control
quantit
rtpcr
presenc
caus
dosedepend
reduct
viral
rna
level
figur
concentr
nm
instanc
observ
reduct
viral
requir
achiev
compar
mrna
antigenom
reduct
level
figur
assay
appli
orthomyxoviru
infect
likewis
observ
dosedepend
inhibit
influenza
wsn
antigenom
level
rel
vehicl
treat
control
figur
parallel
quantif
genom
copi
number
releas
progeni
viru
demonstr
approxim
drop
rel
viral
antigenom
level
correl
reduct
genom
copi
releas
progeni
virion
figur
assess
viral
rdrp
activ
plasmidbas
minireplicon
report
system
confirm
dosedepend
inhibit
rdrp
also
subinfect
set
sinc
luciferas
report
express
fulli
block
compound
concentr
approxim
nm
figur
taken
togeth
data
suggest
indirect
inhibit
viral
polymeras
complex
interact
compound
cellular
cofactor
requir
rdrp
activ
basi
antivir
effect
suggest
differ
viral
pathogen
hostdirect
antivir
approach
potenti
reduc
frequenc
viral
escap
inhibit
compar
direct
target
pathogen
compon
explor
whether
resist
could
induc
experiment
attempt
stepwis
viral
adapt
growth
presenc
compound
comparison
pathogenspecif
mev
rdrp
inhibitor
follow
escal
dose
scheme
inhibitor
concentr
doubl
virusinduc
cytopath
becam
detect
microscop
robust
resist
pathogentarget
control
emerg
rapidli
approxim
time
window
toler
dose
end
adapt
mm
equival
resist
margin
increas
toler
dose
could
detect
day
continu
viral
incub
presenc
substanc
figur
result
consist
hostdirect
mechan
action
suggest
exist
system
barrier
prevent
rapid
viral
escap
inhibit
articl
recent
year
host
celldirect
antivir
experienc
grow
recognit
new
concept
develop
advanc
gener
antivir
potenti
counteract
challeng
preexist
rapidli
emerg
viral
resist
novel
autom
genom
proteom
analys
greatli
advanc
insight
hostpathogen
interact
studi
underscor
notion
sever
cellular
pathway
exploit
viru
replic
support
hypothesi
hostdirect
antivir
may
enjoy
expand
viral
target
rang
render
effect
treatment
sever
relat
viral
diseas
technolog
appli
hostdirect
drug
discoveri
includ
cdna
sirnabas
microarray
analys
combin
pathwayguid
data
mine
lossoffunct
screen
use
aptam
small
oligonucleotid
protein
array
analys
chemic
librari
screen
combin
autom
librari
screen
counter
screen
varieti
relat
viral
pathogen
myxoviru
famili
identifi
candid
scaffold
moder
hittolead
chemistri
adher
profil
hostdirect
antivir
base
sever
line
evid
antivir
activ
host
cell
speciesdepend
indic
specif
interact
distinct
host
factor
rather
viral
compon
host
cellspecif
activ
incompat
compound
dock
conserv
viral
factor
exampl
carbohydr
structur
expos
viral
envelop
glycoprotein
target
antivir
lectin
pradimicin
furthermor
incompat
undesir
unspecif
promiscu
mode
action
compound
ii
affin
panel
human
pathogen
paramyxoviru
famili
well
laboratori
adapt
wild
type
influenza
viru
isol
similar
throughout
averag
ec
concentr
nm
equival
activ
concentr
argu
compound
dock
distinct
viral
compon
suggest
inhibit
distinct
myxoviru
famili
follow
mechan
action
iii
vitro
adapt
attempt
induc
viral
resist
unsuccess
even
extend
exposur
time
drug
full
assess
frequenc
viral
escap
inhibit
certainli
need
includ
vivo
viru
adapt
attempt
suitabl
anim
model
sinc
rate
resist
buildup
may
vari
tissu
cultur
vivo
set
nevertheless
reliabl
induc
resist
less
day
pathogendirect
mev
rdrp
inhibitor
analyz
parallel
fulli
consist
previou
experi
provid
confid
valid
overal
experiment
design
viral
adapt
mechanist
analysi
bioactiv
compound
class
character
expos
cell
timeofaddit
experi
reveal
two
distinct
phenotyp
temporari
cell
cycl
arrest
g
phase
arrest
myxoviru
life
cycl
postentri
step
current
librari
chemic
analog
yet
permit
definit
conclus
whether
activ
adher
discret
structureact
relationship
causal
link
bulk
experiment
data
demonstr
host
cell
cycl
arrest
per
se
inhibitori
effect
replic
paramyxovirus
mev
viru
induc
g
sphase
arrest
infect
lymphocyt
also
found
exposur
infect
cell
alsterpaullon
potent
blocker
g
sphase
cell
cycl
progress
nanomolar
inhibit
cellular
cyclindepend
kinas
affect
extent
viru
replic
even
concentr
exceed
report
alsterpaullon
ec
valu
likewis
consist
notion
antivir
activ
base
cell
cycl
arrest
viru
inhibit
restrict
context
immort
rapidli
divid
tissu
cultur
cell
line
extend
equal
potenc
primari
human
pbmc
revers
cell
cycl
arrest
block
viru
replic
indic
noncoval
dock
target
structur
corrobor
compound
stabil
low
chemic
reactiv
profil
complet
absenc
virucid
activ
preincub
set
inhibit
profil
close
mimick
pathogendirect
blocker
mev
rdrp
target
viral
l
polymeras
protein
block
viral
rdrp
activ
context
viral
infect
minireplicon
report
assay
consist
point
toward
interact
compound
host
cofactor
essenti
rdrp
function
basi
antivir
activ
viral
rdrp
depend
varieti
host
cell
compon
unperturb
cellular
mrna
synthesi
thu
uninterrupt
host
rna
polymeras
function
presenc
compound
exclud
interfer
essenti
transcript
initi
factor
recent
accumul
evid
implic
host
cell
kinas
regul
activ
rdrp
complex
differ
negativestrand
rna
virus
host
cell
kinas
pathway
manipul
paramyxoviru
rdrp
activ
aktmedi
phosphoryl
viral
phosphoprotein
essenti
compon
rdrp
complex
furthermor
akt
activ
upregul
activ
influenza
infect
via
direct
interact
viral
protein
case
mev
howev
publish
data
observ
krumm
plemper
unpublish
demonstr
akt
inhibit
caus
moder
reduct
viru
releas
wherea
titer
cellassoci
progeni
particl
remain
unchang
rule
pathway
direct
target
illumin
intric
regulatori
interact
pathogen
host
provid
wealth
possibl
point
entri
antivir
intervent
futur
identif
molecular
target
carri
high
potenti
understand
interact
may
conceiv
provid
basi
pharmacophor
extract
structuredriven
scaffold
optim
note
central
sulfur
chemic
scaffold
could
potenti
render
molecul
vulner
rapid
phase
oxid
thu
compromis
metabol
stabil
bioavail
instanc
report
flavincontain
monooxygenas
dioxygenas
cytochrom
enzym
catalyz
oxid
alkylaryl
sulfid
sulfoxid
r
howev
high
stabil
presenc
human
hepatocyt
subcellular
fraction
human
plasma
argu
undesir
short
vivo
halflif
substanc
corrobor
good
metabol
stabil
structur
similar
hiv
revers
transcriptas
inhibitor
share
central
connector
achiev
success
clinic
trial
compound
well
toler
phase
studi
singl
multipl
oral
dose
show
drugrel
cn
toxic
creat
clinic
preced
applic
broader
scaffold
although
follow
differ
mechan
action
lack
antiparamyxoviru
activ
structur
similar
provid
suffici
confid
overal
development
potenti
class
recommend
promis
candid
advanc
synthet
optim
toward
preclin
valid
develop
toto
identifi
novel
chemic
class
viral
inhibitor
block
viral
rdrp
activ
host
factormedi
profil
complet
activ
workup
synthet
identif
clinic
lead
analog
requir
fulli
appreci
rang
differ
viral
famili
inhibit
substanc
howev
consid
human
pathogen
myxoviru
famili
primarili
associ
acut
diseas
among
suitabl
hostdirect
antivir
effort
due
anticip
short
treatment
regimen
exclud
resist
may
eventu
emerg
vivo
set
vitro
adapt
effort
support
hypothesi
mechan
action
compound
class
establish
strong
barrier
rapid
viral
escap
inhibit
cell
line
maintain
co
dulbecco
modifi
eagl
medium
supplement
fetal
bovin
serum
vero
african
green
monkey
kidney
epitheli
cell
atcc
stabli
express
human
signal
lymphocyt
activ
molecul
call
studi
veroslam
cell
babi
hamster
kidney
cell
stabli
express
polymeras
cell
incub
everi
third
passag
presenc
geneticin
concentr
mgml
lipofectamin
invitrogen
use
cell
transfect
peripher
blood
mononuclear
cell
pbmc
prepar
overlay
whole
blood
sampl
mix
healthi
human
donor
emori
univers
institut
review
board
approv
phlebotomi
healthi
adult
research
infecti
diseas
immunolog
ficol
hypaqu
solut
follow
centrifug
minut
room
temperatur
remov
interphas
materi
red
blood
cell
lyse
rbc
lysi
solut
sigma
follow
repeat
wash
extract
pbmc
phosphat
buffer
salin
transfer
tissu
cultur
plate
precoat
polyllysin
sigma
primari
human
cell
line
obtain
promocel
germani
viru
strain
use
studi
mev
isol
genotyp
mevalaska
muv
strain
south
africa
rsv
strain
long
laboratori
adapt
influenza
strain
wsn
swineorigin
influenza
viru
isol
soiv
texa
mexico
vaccinia
viru
sindbi
viru
prepar
viru
stock
cell
permiss
viru
amplifi
veroslam
vero
atcc
madindarbi
canin
kidney
mdck
infect
incub
cellassoci
paramyxoviru
vaccinia
viru
particl
harvest
scrape
cell
optimem
invitrogen
follow
releas
viru
two
consecut
freezethaw
cycl
influenza
viru
sindbi
viru
particl
harvest
cell
cultur
supernat
titer
mev
muv
determin
tissu
cultur
infect
dose
tcid
titrat
accord
spearmankarb
method
describ
titer
virus
determin
plaqu
assay
permiss
cell
determin
genom
copi
number
releas
progeni
influenza
particl
strain
wsn
soiv
texa
mexico
cultur
supernat
infect
mdck
cell
cellswel
plate
format
harvest
total
rna
prepar
use
qiacub
autom
extractor
qiaamp
viral
rna
mini
kit
reagent
purifi
rna
subject
quantit
real
time
qrt
pcr
analysi
use
appli
biosystem
fast
realtim
pcr
system
qrtpcr
taqman
fast
viru
master
mix
appli
biosystem
primer
probe
base
recent
report
univers
reactiv
influenza
strain
includ
recent
soiv
isol
gener
qrtpcr
standard
genom
segment
seven
influenza
awsn
subclon
vector
invitrogen
copi
number
result
standard
calcul
use
promega
biomath
calcul
tool
http
wwwpromegacom
biomath
taqman
reaction
serial
dilut
linear
plasmid
rang
amplifi
parallel
chemic
synthesi
compound
achiev
previous
describ
synthesi
n
substanc
figur
analog
achiev
outlin
schemat
figur
prepar
inhibitor
stock
compound
dissolv
mm
dmso
veroslam
cell
infect
mevalaska
moi
pfucel
presenc
inhibitor
analyz
rang
mm
nm
twofold
dilut
hour
postinfect
cell
monolay
subject
crystal
violet
stain
crystal
violet
ethanol
absorb
dri
plate
nm
determin
virusinduc
cytopath
calcul
accord
formula
rel
cpe
experimentalminimum
maximumminimum
minimum
refer
infect
vehicletr
well
maximum
mockinfect
well
cell
infect
specifi
myxoviru
moi
pfucel
paramyxovirus
assess
pfucel
influenza
virus
vaccinia
viru
sindbi
viru
presenc
rang
compound
concentr
equival
volum
solvent
dmso
incub
presenc
compound
vehicl
treat
control
approach
end
logarithm
growth
phase
progeni
viral
particl
harvest
titer
tcid
titrat
plaqu
assay
taqman
realtim
pcr
respect
describ
plot
viru
titer
function
compound
concentr
allow
quantit
assess
resist
applic
inhibitori
concentr
calcul
use
variabl
slope
four
paramet
nonlinear
regressionfit
algorithm
embed
prism
softwar
packag
graphpad
softwar
vitro
assess
metabol
plasma
stabil
mix
liver
fraction
protein
concentr
mgml
pool
mix
gender
human
xenotech
final
concentr
mm
reaction
initi
addit
cofactor
mm
nadph
mm
mm
uridin
acid
mm
potassium
chlorid
mm
magnesium
chlorid
mm
potassium
phosphat
buffer
ph
sampl
incub
mix
aliquot
remov
minut
subject
reversedphas
lcmsm
appli
biosystem
api
qtrap
heat
nebul
turbo
ionspray
analysi
peak
area
measur
calcul
half
life
percent
input
compound
remain
accord
formula
linear
regress
analysi
log
transform
peak
area
versu
input
remain
peak
area
test
compound
x
peak
area
test
compound
posit
control
assess
metabol
compet
liver
fraction
propranolol
verapamil
sigma
analyz
parallel
articl
determin
compound
plasma
stabil
articl
mix
freshli
prepar
human
plasma
final
concentr
mm
incub
minut
aliquot
remov
distinct
time
point
indic
analyz
lcmsm
detect
compound
nm
valu
express
percent
compound
remain
time
rel
amount
compound
present
start
time
point
activ
prolifer
hela
cell
expos
mm
hydroxyurea
mm
nocodazol
ngml
hour
follow
resuspens
buffer
mm
citratepo
ph
mm
edta
sucros
triton
stain
buffer
ii
mm
citratepo
ph
sodium
chlorid
mgml
acridin
orang
describ
green
fluoresc
nm
result
dna
intercal
acridin
orang
measur
use
bd
lsrii
flow
cytomet
flowjo
softwar
tree
star
data
analysi
comparison
unstain
stain
solventonli
expos
cell
examin
parallel
cell
lyse
ripa
buffer
mm
triscl
ph
deoxychol
sodium
dodecylsulf
mm
sodium
chlorid
mm
sodium
fluorid
mm
edta
mm
pmsf
proteas
inhibitor
aliquot
equal
total
concentr
clear
lysat
min
mix
buffer
mm
tri
ph
urea
sodium
dodecyl
sulfat
sd
mm
edta
bromphenol
blue
dithiothreitol
denatur
min
sampl
fraction
sdspolyacrylamid
gel
blot
polyvinyliden
difluorid
pvdf
membran
millipor
subject
enhanc
chemiluminesc
detect
pierc
use
specif
antisera
direct
phosphoryl
nonphosphoryl
b
kinas
cell
signal
technolog
gapdh
abcam
cytosol
tail
mev
f
protein
influenza
awsn
viru
thermo
scientif
immunostain
pvdf
membran
develop
use
chemidoc
xr
digit
imag
system
biorad
horseradish
peroxidas
conjug
antispeci
igg
mous
rabbit
antibodi
densitometri
signal
quantifi
use
quantityon
softwar
packag
biorad
vero
cell
seed
densiti
cell
incub
presenc
mm
vehicl
hour
cell
wash
extens
reseed
densiti
cell
per
well
follow
continu
incub
assess
lifedead
cell
number
everi
hour
use
countess
autom
cell
counter
invitrogen
cell
reseed
fastest
grow
cultur
approach
confluenc
growth
rate
calcul
time
interv
use
prism
softwar
packag
graphpad
softwar
inc
base
formula
exp
k
x
equal
life
cell
number
valu
start
time
k
growth
constant
equal
ln
doublingtim
cell
infect
either
recombin
mev
edmonston
recmevedm
vero
cell
moi
influenza
awsn
mdck
cell
moi
follow
remov
inocula
one
hour
postinfect
addit
growth
media
mm
mm
mev
infect
well
receiv
addit
fusion
inhibitori
peptid
fip
bachem
mm
prevent
prematur
breakdown
monolay
viral
cpe
vehicl
control
well
prior
rna
extract
twentyfour
influenza
awsn
forti
recmevedm
hour
postinfect
total
rna
prepar
well
use
qiacub
autom
extractor
rneasi
mini
kit
qiagen
subject
revers
transcript
use
superscript
ii
revers
transcriptas
invitrogen
rna
sampl
origin
recmevedm
infect
cell
antigenomespecif
primer
oligodt
primer
viral
mrna
gapdh
quantif
use
cdna
prime
case
sampl
origin
influenza
awsn
infect
cell
primer
cdna
synthesi
antigenom
oligodt
mrna
canin
gapdh
realtim
reaction
carri
use
appli
biosystem
fast
realtim
pcr
system
iq
fast
sybr
green
supermix
rox
biorad
probe
fragment
np
junction
mev
antigenom
rna
tctgatatttctgac
fragment
mev
f
mrna
fragment
human
gapdh
sabiosci
proprietari
primer
fragment
influenza
awsn
segment
seven
influenza
awsn
antigenom
rna
fragment
canin
gapdh
qiagen
proprietari
primer
melt
curv
gener
end
reaction
verifi
amplif
singl
product
calcul
ddc
valu
ct
valu
obtain
sampl
normal
gapdh
refer
dc
valu
sampl
normal
fiptreat
control
final
quantif
base
three
independ
experi
treatment
condit
rt
primer
set
assess
triplic
assess
rel
quantiti
cellular
mrna
hela
cell
incub
presenc
mm
final
concentr
mm
actinomycin
mgml
vehicl
six
hour
follow
prepar
total
rna
describ
quantit
taqman
rtpcr
achiev
use
taqman
fast
master
mix
appli
biosystem
combin
proprietari
primer
probe
set
specif
induc
myeloid
leukemia
cell
differenti
protein
mapk
phosphatas
ankyrin
repeat
soc
boxcontain
protein
encod
mrna
appli
biosystem
sampl
standard
gapdh
normal
valu
express
rel
equal
analyz
vehicletr
control
effector
cell
popul
cellswel
cotransfect
mg
mev
h
f
express
plasmid
inhibit
fusion
cell
overlay
effector
cell
incub
presenc
mm
fusion
inhibitori
peptid
bachem
singl
transfect
plasmid
encod
mev
f
serv
control
target
cell
cellswel
transfect
mg
report
plasmid
encod
firefli
luciferas
control
promot
two
hour
posttransfect
modifi
vaccinia
viru
ankara
express
polymeras
moi
pfu
cell
ad
effector
cell
follow
incub
h
target
cell
detach
overlaid
wash
effector
cell
ratio
incub
presenc
differ
concentr
indic
four
hour
postoverlay
cell
lyse
use
bright
glo
lysi
buffer
promega
luciferas
activ
determin
luminesc
counter
perkinelm
addit
britelit
substrat
perkinelm
instrument
arbitrari
valu
analyz
subtract
rel
background
provid
valu
control
valu
normal
refer
construct
indic
figur
legend
averag
background
valu
valu
obtain
refer
construct
qualit
assess
transfect
veroslam
cell
photograph
hour
posttransfect
magnif
viru
preincub
assay
infecti
mevalaska
particl
incub
minut
presenc
mm
final
concentr
vehicl
follow
dilut
growth
media
transfer
veroslam
cellswel
correspond
final
compound
concentr
preincub
nm
moi
refer
well
kept
mm
durat
experi
cellassoci
viral
particl
harvest
hour
postinfect
infecti
titer
determin
tcid
titrat
assess
cell
prime
veroslam
cell
well
incub
presenc
mm
one
hour
indic
time
point
preinfect
follow
wash
incub
growth
media
immedi
infect
cell
reseed
densiti
per
well
infect
mevalaska
moi
pfucel
inocula
replac
growth
media
four
hour
postinfect
cell
incub
approxim
hour
cellassoci
viral
particl
harvest
infecti
titer
determin
tcid
minireplicon
assay
bsr
cell
well
transfect
plasmid
dna
encod
mevl
mg
mevn
mg
mevp
mg
mg
mev
luciferas
minigenom
report
plasmid
control
well
includ
ident
amount
report
helper
plasmid
lack
lencod
plasmid
time
transfect
ad
specifi
control
well
receiv
vehicl
comparison
thirtysix
hour
posttransfect
cell
lyse
bright
glo
lysi
buffer
rel
luciferas
activ
determin
use
britelit
substrat
luminesc
counter
outlin
adapt
carri
essenti
previous
describ
briefli
veroslam
cell
infect
mevalaska
moi
pfuml
incub
presenc
gradual
increas
concentr
start
mm
equal
infect
cell
treat
viru
polymeras
target
rdrp
inhibitor
examin
parallel
cultur
becam
confluent
cell
reseed
continu
incub
presenc
compound
concentr
detect
extens
celltocel
fusion
cellassoci
viral
particl
harvest
dilut
use
parallel
infect
fresh
cell
monolay
presenc
compound
unchang
doubl
concentr
cultur
treat
highest
compound
concentr
virusinduc
cytopath
becam
detect
use
adapt
approach
termin
day
continu
incub
virusinduc
cytopath
readili
detect
presenc
mm
compound
accord
previou
result
